Login to Your Account

Post Evomela CRL, Spectrum's NMIBC trial starts as planned

By Jennifer Boggs
Managing Editor

Monday, October 26, 2015

Last week's unexpected FDA complete response letter for multiple myeloma drug Evomela hasn't disrupted Spectrum Pharmaceuticals Inc.'s plan for bladder cancer candidate apaziquone.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription